SG/CALL/VERTEX PHARMACEUTICALS/360/0.1/17.01.25 | Market Closed - Deutsche Boerse AG 15:39:33 2024-06-28 EDT | ||
| 12.08 EUR | -1.55% |
|
| Current month | +12.27% | ||
| 1 month | +19.72% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 12.08 | -1.55% |
| 24-06-27 | 12.27 | +0.16% |
| 24-06-26 | 12.25 | +1.24% |
| 24-06-25 | 12.1 | -2.42% |
| 24-06-24 | 12.4 | +3.33% |
Delayed Quote Deutsche Boerse AG
Last update June 28, 2024 at 03:39 pm
More quotesStatic data
| Product type | Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SQ864W |
| ISIN | DE000SQ864W4 |
| Date issued | 2023-02-16 |
| Strike | 360 $ |
| Maturity | 2025-01-17 (202 Days) |
| Parity | 10 : 1 |
| Emission price | 4.19 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.34 € |
|---|---|
| Lowest since issue | 3.27 € |
| Delta | 0x |
| Omega | 0.000000 |
| Premium | 0x |
| Gearing | 0x |
| Moneyness | 1.302 |
| Difference Strike | -108.7 $ |
| Difference Strike % | -30.20% |
| Intrinsic value | 10.15 |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
468.7
USD
Average target price
468.3
USD
Spread / Average Target
-0.10%
- Stock Market
- Warrants
- Warrant
